Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

Samsung Medical Center

Status: Suspended

Conditions: CYP19; Polymorphism; Aromatase Inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT01137136

2009-11-035

Details and patient eligibility

About

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Enrollment: 300 estimated patients

Sex: Female

Ages: Under 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• hormone receptor positiveBreast cancer patient
• postmenopausal women
• first user of aromatase inhibitor

Exclusion criteria

• premenopausal
• The patient who take the other antihormonal therapy
• osteoporosis patients

Trial design

300 participants in 1 patient group

SMAC (SMc AI user Cohort)

Description:

All patients who took the AI (Aromatase inhibitor)will be enrolled